THE IMPACT OF BODY MASS INDEX ON THE RISK OF DEVELOPING SERIOUS ADVERSE EVENTS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER
DOI:
https://doi.org/10.32782/2226-2008-2025-1-7Keywords:
bevacizumab, lung cancer, adverse events, sex, survivalAbstract
One of the essential drugs used to treat patients with metastatic non-small cell lung cancer (mNSCLC) is bevacizumab. Bevacizumab is associated with a significant number of severe adverse events. The relationship between body composition and the risk of hemorrhagic, thromboembolic events, and hypertension remains unclear. Therefore, our study aimed to establish a correlation between survival, these adverse events, and body mass index (BMI). Materials and methods. Eighty-seven patients with mNSCLC treated in the Sumy Regional Clinical Oncology Center were involved in the retrospective study. Data on sex, age, weight, height of patients, results of coagulogram, and blood count tests were collected from the primary medical documentation no more than one week before the start of bevacizumab therapy. BMI was calculated based on data on the weight and height of patients according to the formula: weight/height2 (kilograms/per square meter). Patients with BMI <25 kg/m2 were included in the underweight and normal weight groups. Those whose BMI was ≥25 kg/m2 were included in the overweight and obese group. Adverse event severity was determined using the Common Terminology Criteria for Adverse Events (CTCAE, version 5). Chi2 test for categorical variables, Fisher’s exact test, multivariate Cox regression analysis and Kaplan-Meier method were used for statistical analysis. Results. According to the results of univariate analysis, it was established that each clinicopathological characteristic does not have a statistically significant correlation with BMI. However, multivariate analysis showed that patient sex (P=0.011) and blood platelet level (P=0.045) correlated with OS. The median overall survival (OS) in women was 16.0 months versus 9.1 months in men. Median OS in patients with platelets less than 280 g/L was 13.5 months versus 7.4 months in those with 280 g/L or higher. Conclusions. BMI does not impact on OS and risk of thromboembolism, bleeding, and hypertension in patients with mNSCLC receiving bevacizumab therapy. Women and those whose baseline platelet count is less than 280 g/L have better survival.
References
Fedorenko Z. Cancer in Ukraine, 2021–2022. Incidence, mortality, prevalence, and other relevant statistics. Bulletin of the National Cancer Registry of Ukraine, Vol. 24 Available from: http://ncru.inf.ua/publications/BULL_24/index.htm.
Perdrizet K, Leighl NB. The Role of angiogenesis inhibitors in the era of immune checkpoint inhibitors and targeted therapy in metastatic non-small cell lung cancer. Curr Treat Options Oncol. 2019; 20(3):21. doi: 10.1007/s11864-019-0617-6. PMID: 30778772.
Van Cauwenberge J, Van Baelen K, Maetens M, et al. Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review. Breast Cancer Res. 2024; 26(1):81. doi: 10.1186/s13058-024-01832-7.
Pfeiler G, Hlauschek D, Mayer EL, Deutschmann C, Kacerovsky-Strobl S. Impact of BMI in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial. J Clin Oncol. 2023; 41(33):5118–5130. doi: 10.1200/JCO.23.00126.
Lipsyc-Sharf M, Ballman KV, Campbell JD, et al. Age, body mass index, tumor subtype, and racial and ethnic disparities in breast cancer survival. JAMA Netw Open. 2023; 6(10):e2339584. doi: 10.1001/jamanetworkopen.2023.39584. Erratum in: JAMA Netw Open. 2023; 6(11):e2348174. doi: 10.1001/jamanetworkopen.2023.48174.
Vithayathil M, D’Alessio A, Fulgenzi CAM, et al. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma. Hepatol Int. 2023; 17(4):904–914. doi: 10.1007/s12072-023-10491-3.
Assoun S, Brosseau S, Steinmetz C, Gounant V, Zalcman G. Bevacizumab in advanced lung cancer: state of the art. Future Oncol. 2017; 13(28):2515–2535. doi: 10.2217/fon-2017-0302.
Ou WF, Liao PY, Hsu YW, et al. Outcome of Thromboembolic Events and Its Influence on Survival Time of Advanced NSCLC Patients Treated with Antiangiogenic Therapy. Cancer Manag Res. 2023; 15:1251–1262. doi: 10.2147/CMAR.S430868.
Huang L, Yin Y, Qian D, et al. IRF7 and IFIT2 in mediating different hemorrhage outcomes for non-small cell lung cancer after bevacizumab treatment. J Thorac Dis. 2023; 15(4):2022–2036. doi: 10.21037/jtd-23-389.
Pasquiers B, Benamara S, Felices M, Ternant D, Declèves X, Puszkiel A. Translation of Monoclonal Antibodies Pharmacokinetics from Animal to Human Using Physiologically Based Modeling in Open Systems Pharmacology (OSP) Suite: A Retrospective Analysis of Bevacizumab. Pharmaceutics. 2023; 15(8):2129. doi: 10.3390/pharmaceutics15082129.
Grinshpun B, Thorsteinson N, Pereira JN, et al. Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies. MAbs. 2021; 13(1):1932230. doi: 10.1080/19420862.2021.1932230.
Yin A, Ettaieb MHT, Swen JJ, et al. Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. Clin Pharmacokinet. 2021; 60(1):89–102. doi: 10.1007/s40262-020-00913-y.
Grevys A, Frick R, Mester S, et al. Antibody variable sequences have a pronounced effect on cellular transport and plasmahalf-life. iScience. 2022; 25(2):103746. doi: 10.1016/j.isci.2022.103746.
Heinhuis KM, Beijnen JH, Hendrikx JJMA. Follow up survey for implementation of fixed-dosing of monoclonal antibodies. Int J Clin Pharm. 2020; 42(1):3–6. doi: 10.1007/s11096-020-00971-z.
Hendrikx JJMA, Haanen JBAG, Voest EE, Schellens JHM, Huitema ADR, Beijnen JH. Fixed dosing of monoclonal antibodies in oncology. Oncologist. 2017; 22(10):1212–1221. doi: 10.1634/theoncologist.2017-0167.
Hummel M, Bosje T, Shaw A, et al. A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab. J Cancer Res Clin Oncol. 2022; 148(2):487–496. doi: 10.1007/s00432-021-03628-0.
Anderson R, Rapoport BL, Steel HC, Theron AJ. Pro-tumorigenic and thrombotic activities of platelets in lung cancer. Int J Mol Sci. 2023; 24(15):11927. doi: 10.3390/ijms241511927.
Smorodska O, Moskalenko Yu, Kononenko M, Ivanov S. Inflammation indexes as predictors of recurrence in patients with surgically resected non-small cell lung cancer. East. Ukr. Med. J. [Internet]. 2022 Dec. 29 [cited 2024 Jul. 14]; 10(4):379–88. https://doi.org/10.21272/eumj.2022;10(4):379-388.
Dudiki T, Veleeparambil M, Zhevlakova I, et al. Mechanism of tumor-platelet communications in cancer. Circ Res. 2023; 132(11):1447–1461. doi: 10.1161/CIRCRESAHA.122.321861.
Larsen JB, Hojbjerg JA, Hvas AM. The role of platelets in cancer-related bleeding risk: a systematic review. Semin Thromb Hemost. 2020; 46(3):328–341. doi: 10.1055/s-0039-3402429.
